menu
    • menu
    [{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Topical Ocular Formulation of Aerpio Pharmaceutical\u2019s AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"VE-PTP","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"VE-PTP","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aerpio Pharmaceuticals and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for I-SPY COVID Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Razuprotafib","moa":"PTP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"VE-PTP","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"MTEC","pharmaFlowCategory":"D","amount":"$5.1 million","upfrontCash":"Undisclosed","newsHeadline":"Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for Treatment of ARDS in COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Razuprotafib","moa":"PTP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aerpio Pharmaceuticals \/ MTEC","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ MTEC"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerpio and Quantum Leap Doses First Patients with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"PTP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare Collaborative","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare Collaborative"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"VE-PTP","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerpio Dosed First Patient with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"Tie2 activator\/Vascular endothelial protein tyrosine phosphatase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aerpio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical's Razuprotafib in I-SPY COVID Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"Tie2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous solution","sponsorNew":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare"}]

    Find Clinical Drug Pipeline Developments & Deals for Razuprotafib

    Menu

    Razuprotafib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Razuprotafib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Quantum Leap Healthcare

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical's Razuprotafib in I-SPY CO...

                            Details : The I-SPY COVID Trial was halted by Quantum Leap Healthcare Collaborative because Aerpio's razuprotafib was difficult to administer in the setting of COVID-19, with 30% of patients discontinuing the agent due to disease-related hypotension.

                            Brand Name : AKB-9778

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 05, 2021

                            Lead Product(s) : Razuprotafib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Quantum Leap Healthcare

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Razuprotafib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aerpio Dosed First Patient with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in ...

                            Details : Razuprotafib a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase, is being developed as a treatment for open angle glaucoma, and the Company intends to investigate the therapeutic potential of razuprotafib in ot...

                            Brand Name : AKB-9778

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 26, 2020

                            Lead Product(s) : Razuprotafib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Razuprotafib

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma Trial

                            Details : The study is designed to evaluate the safety and efficacy of a topical ocular formulation of razuprotafib in approximately 195 patients followed over a 28-day period, and patients must undergo a 28-day washout prior to randomization.

                            Brand Name : AKB-9778

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 15, 2020

                            Lead Product(s) : Razuprotafib

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Razuprotafib,Remdesivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Quantum Leap Healthcare

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aerpio and Quantum Leap Doses First Patients with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Criti...

                            Details : First patient with razuprotafib in the I-SPY COVID Trial, a phase 2 platform trial aimed at improving treatment of acute respiratory distress syndrome (ARDS) in severely ill COVID-19 (adult) patients.

                            Brand Name : AKB-9778

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 01, 2020

                            Lead Product(s) : Razuprotafib,Remdesivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Quantum Leap Healthcare

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Razuprotafib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : MTEC

                            Deal Size : $5.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib...

                            Details : Aerpio is developing a selective small molecule inhibitor of vascular endothelial protein tyrosine phosphatase, razuprotafib (AKB-9778), that restores Tie2 pathway activation in endothelial cells to stabilize blood vessels during vascular injury and infl...

                            Brand Name : AKB-9778

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 04, 2020

                            Lead Product(s) : Razuprotafib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : MTEC

                            Deal Size : $5.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Razuprotafib

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial

                            Details : Aerpio Pharmaceuticals has commenced patient enrollment in its double-blind, placebo-controlled Phase 2 trial in patients with elevated intraocular pressure (IOP) associated with open angle glaucoma (OAG) or ocular hypertension (OHT).

                            Brand Name : AKB-9778

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 24, 2020

                            Lead Product(s) : Razuprotafib

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Razuprotafib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Quantum Leap Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aerpio Pharmaceuticals and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for I-...

                            Details : The collaboration aims at evaluating razuprotafib in a new randomized, investigational treatment arm in the I-SPY COVID Trial for the treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 27, 2020

                            Lead Product(s) : Razuprotafib

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Quantum Leap Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Razuprotafib,Prostaglandin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort

                            Details : The Phase 1b trial is a randomized, double-masked study designed to assess increasing concentrations of AKB-9778 dosed topically as eye drops.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 10, 2020

                            Lead Product(s) : Razuprotafib,Prostaglandin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Aerpio Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Razuprotafib,Prostaglandin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Topical Ocular Formulation of Aerpio Pharmaceutical’s AKB-9778 Product Candidate Produced IOP Lowering with ...

                            Details : Topical ocular administration of AKB-9778 was well tolerated over seven days in cohort 5.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 08, 2020

                            Lead Product(s) : Razuprotafib,Prostaglandin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth